Hormone replacement therapy and risk of lymphomas and myelomas

The relation between post-menopausal hormone replacement therapy (HRT) and lymphoid neoplasms was analysed using data from a case–control study conducted in northern Italy between 1983 and 1992. Cases included 26 incident, histologically confirmed, post-menopausal female patients of Hodgkin's Disease (HD), 145 non-Hodgkin's lymphomas (NHL) and 65 multiple myelomas (MM), between 45 and 79 years of age. The control group comprised 361 women (age range 45–79 years) admitted to the same network of hospitals for acute, non-neoplastic conditions. The multivariate odds ratio (OR) for ever HRT users was 0.7 [95% confidence interval (CI) 0.2–2.8] for HD, 0.7 (95% CI 0.3–1.4) for NHL, and 0.2 (95% CI 0.1–1.0) for MM. No clear pattern of association was found for duration or recently of use. Despite the relatively small number of cases, due to the rarity of the disease, and the low frequency of HRT use in this population, these findings provide additional information for any global risk–benefit assessment of HRT use.

[1]  N. Keiding,et al.  Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe , 2004, International journal of cancer.

[2]  J. Forsberg.  Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis , 1984, Archives of Toxicology.

[3]  Ana Maria Lopez,et al.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. , 2003, JAMA.

[4]  E. Fernández,et al.  Hormone replacement therapy and cancer risk: A systematic analysis from a network of case‐control studies , 2003, International journal of cancer.

[5]  J. Cerhan,et al.  Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[7]  C. la Vecchia,et al.  Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. , 2001, Journal of clinical epidemiology.

[8]  C. la Vecchia,et al.  Menopause, hormone replacement therapy and cancer. , 2001, Maturitas.

[9]  L. Bernstein,et al.  Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Shapiro,et al.  A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  A. Strasser,et al.  Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. , 2000, Blood.

[12]  C. la Vecchia,et al.  Correlates of hormone replacement therapy use in Italian women, 1992-1996. , 1999, Maturitas.

[13]  C. la Vecchia,et al.  A case-control study of reproductive factors and risk of lymphomas and myelomas. , 1997, Leukemia research.

[14]  S. Glaser.  Reproductive factors in Hodgkin's disease in women: a review. , 1994, American journal of epidemiology.

[15]  L. Bernstein,et al.  Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. , 1992, Cancer research.

[16]  T. Dragani,et al.  Libri Ricevuti: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1992 .

[17]  C. la Vecchia,et al.  The epidemiology of non-Hodgkin's lymphoma in the north-east of Italy: a hospital-based case-control study. , 1989, Leukemia research.

[18]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.